Professor Gareth Thomas of Southampton University Awarded Second Grant from Cancer Research UK for Further Evaluation of GKT831 in Oncology

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that Professor Gareth Thomas of the University of Southampton, United Kingdom (UK), was awarded a Biotherapeutics Drug Discovery Project grant by Cancer Research UK (CRUK), a leading cancer research and awareness organization based in the UK, to conduct a research program focused on the role of NOX inhibition in oncology. The £260 thousand grant will support the research program entitled “Combination immunotherapy for breast cancer: targeting cancer-associated fibroblasts to improving therapeutic vaccination.” This is the second grant provided by CRUK to Professor Thomas for the evaluation of NOX inhibitors in oncology.